|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/33894
| Title: | THE ROLE OF EXCIPIENTS IN THE CONTROL OF NITROSAMINE IMPURITIES IN TABLETS AND CAPSULES |
| Authors: | Ciomaia, Nelea Anton, Mihail Ciobanu, Nicolae |
| Keywords: | Nitrosamines;pharmaceutical excipients;genotoxic impurities |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Ciomaia, Nelea; Anton, Mihail; Ciobanu, Nicolae. THE ROLE OF EXCIPIENTS IN THE CONTROL OF NITROSAMINE IMPURITIES IN TABLETS AND CAPSULES. In: MedEspera 2026, p. 74. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Nitrosamine impurities represent an important concern in pharmaceutical quality assurance due to their potential genotoxic and carcinogenic effects. The detection of these compounds in several medicinal products has led to increased regulatory attention and reassessment of manufacturing processes. Although the initial investigations focused mainly on the synthesis of active pharmaceutical ingredients, recent studies indicate that pharmaceutical excipients may also influence the formation or control of nitrosamines in drug products. In solid dosage forms such as tablets and capsules, interactions between excipients, active substances, and environmental factors may affect the risk of nitrosamine contamination. Aim of study. To evaluate the role of pharmaceutical excipients in the formation and control of nitrosamine impurities in tablets and capsules based on the analysis of current scientific literature and regulatory guidance. Methods and materials. The study was conducted as a narrative literature focused on nitrosamine impurities in pharmaceutical products. Scientific information was collected from international databases such as PubMed, Scopus, Web of Science and ScienceDirect, as well as from regulatory documents issued by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the International Council for Harmonization (ICH). The analysis focused on mechanisms of nitrosamine formation, their toxicological relevance, and the possible contribution of excipients used in solid pharmaceutical formulations. Results. The analysis indicates that nitrosamine formation in medicinal products may occur when nitrosating agents interact with amine-containing compounds under favorable conditions. Excipients frequently used in tablets and capsules, including lactose, microcrystalline cellulose, and povidone, may indirectly influence these processes by introducing trace impurities or by affecting formulation parameters such as moisture, pH and storage stability. Environmental factors such as humidity, temperature and manufacturing conditions may further facilitate slow nitrosation reactions during processing or storage. Current regulatory recommendations emphasize systematic risk assessment throughout the product lifecycle, including evaluation of excipient quality, supplier control, compatibility studies, and the use of sensitive analytical methods for nitrosamine detection. Conclusions. Pharmaceutical excipients may play an important role in both the formation and control of nitrosamine impurities in solid dosage forms. Careful excipient selection, detailed risk assessment, and implementation of appropriate quality control strategies are essential for minimizing nitrosamine contamination and ensuring the safety and quality of medicinal products. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/33894 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|